BI
CLDX icon

BVF Inc’s Celldex Therapeutics CLDX Stock Holding History

BVF Inc’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-154,000
Closed -$4.15M – 81
2022
Q2 		$4.15M Buy
+154,000
New +$4.47M 0.2% 60
2020
Q4 		– Sell
-3,066,797
Closed -$45.5M – 71
2020
Q3 		$45.5M Buy
3,066,797
+326,797
+12% +$3.83M 2.48% 13
2020
Q2 		$35.6M Buy
+2,740,000
New +$12.1M 2.2% 19

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BVF Inc's CLDX Position: Q3 2022 in Review

BVF Inc sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 154,000 shares — an estimated $4.15M sold.

BVF Inc first reported a position in CLDX in Q2 2020 and held it in 3 quarters. The position peaked at $45.5M in Q3 2020. 158 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • BVF Inc reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • BVF Inc sold 154,000 Celldex Therapeutics shares in Q3 2022, an estimated $4.15M.
  • BVF Inc first reported a position in Celldex Therapeutics in Q2 2020 and held it in 3 quarters.
  • BVF Inc's Celldex Therapeutics position peaked at $45.5M in Q3 2020.
  • 158 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on BVF Inc's 13F filing for Q3 2022, filed 14 Nov 2022.